Thymosin Beta-4 (TB4) is a naturally occurring 43–amino acid protein present in most human and animal cells. It is part of the actin-sequestering protein family and plays a central role in tissue regeneration, angiogenesis, cell migration, and wound healing. TB4 has been studied for its ability to repair tissue after injury, promote new blood vessel growth, and reduce inflammation. Unlike TB-500, which is a shorter synthetic fragment of TB4, full-length TB4 is less commonly available for research but has broader biological activity. Thymosin Beta-4 remains experimental and is not FDA-approved for therapeutic use.
How It Is Used in Research Settings
- Studied for enhancing wound healing and accelerating tissue repair.
- Explored in cardiovascular research for myocardial and vascular regeneration after ischemic injury.
- Investigated in ophthalmology for corneal healing and repair of eye injuries.
- Examined for its role in neuroprotection and central nervous system repair models.
Proposed Uses (Research Areas)
- Tissue repair and regenerative medicine research.
- Cardiovascular and vascular regeneration studies.
- Ophthalmology and corneal healing research.
- Neurodegenerative disease and neural repair models.
- Wound healing and dermatological studies.
How It Is Dosed in Research Settings
- Injectable (Subcutaneous or Intramuscular): Animal and experimental studies have used a wide range of doses, often 2–10 mg several times weekly.
- Topical or ophthalmic formulations: Studied in gels, creams, or eye drops for wound and corneal healing.
- Cycle length: Research protocols vary, from short courses (7–14 days for wound healing) to longer studies lasting weeks or months in regenerative models.
- Handling: Supplied as lyophilized powder or solution; requires refrigeration and protection from light.
Important Considerations
- Regulatory status: TB4 is not FDA-approved; research use has been most prominent in Russia, China, and preclinical models.
- Evidence base: Preclinical studies demonstrate strong regenerative potential, though large-scale clinical validation is limited.
- Safety: Generally well tolerated in experimental settings, but long-term human safety remains uncertain. Theoretical concerns include undesired angiogenesis or fibrosis.
Disclaimer
This material is provided for educational purposes only and summarizes published research on Thymosin Beta-4 (TB4).
It is not medical advice. TB4 is experimental, not FDA-approved, and should not be viewed as a therapy for medical use.
This peptide is for research use only.